F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline Pharmaceuticals Limited (U.K.), Novartis International AG (Switzerland), Bristol-Myers Squibb (U.S.), Eisai Co. Ltd (Japan), Biogen Idec (U.S.), ERYtech Pharma (France) and Celgene Corporation (U.S.)
(PRWEB) January 29, 2015
The report "Leukemia Therapeutics Market" analyzes and studies the major market drivers, restraints, and opportunities in North America, & Europe.
Browse market data tables and in-depth TOC on Leukemia Therapeutics Market (Acute/Chronic Lymphocytic Leukemia & Acute/Chronic Myeloid Leukemia) Pipeline Assessment & Global Market Forecast (2010 - 2020).
Early buyers will receive 10% customization on reports.
Leukemia is the cancer of the white blood cells or the bone marrow. It occurs due to an abnormal increase in the count of white blood cells. It is identified by the spread of the illnesses (either acute or chronic), and by the type of the blood cells that is affected (lymphocytic or myelocytic). This type of cancer can again be categorized into acute lymphoblastic leukemia (ALL), which accounts for about 12%, chronic lymphocytic leukemia (CLL) which accounts for 35%, acute myelogenous leukemia (AML) which accounts for 29%, and chronic myelogenous leukemia (CML) which accounts for 11% of the total leukemia.
The leukemia therapeutics market was evaluated at $6.3 billion in 2010 and is expected to reach $11.3 billion by 2020 at a CAGR of 3.84% between 2015 and 2020. The market was dominated by therapeutics of chronic myeloid leukemia in 2010. However, in 2020, the market is expected to be equally dominated by therapeutics of acute lymphocytic leukemia and chronic myeloid leukemia, with sales amounting to $3.91 billion and $3.58 billion respectively.
According to reports of WHO, leukemia is expected to be more prominent in the developed world such as North America and Europe due to genetic factor. The other causes which add to the count are environmental factors and radiation exposures.
The U.S. dominates the leukemia drug market in North America with 62% share; whereas Germany dominates the market of Europe with 31.05% share.
The major players in the market include F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline Pharmaceuticals Limited (U.K.), Novartis International AG (Switzerland), Bristol-Myers Squibb (U.S.), Eisai Co. Ltd (Japan), Biogen Idec (U.S.), ERYtech Pharma (France) Celgene Corporation (U.S.), Genmab A/S (Denmark), Cephalon Inc. (U.S.), Clavis Pharma (Norway), and Pfizer Inc. (U.S.).
Speak to our Analyst at http://www.marketsandmarkets.com/speaktoanalyst.asp?id=223
Browse Related Reports:
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market – (Pipeline Forecast & Market Forecast in G8 Countries) (2011 – 2020)
Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. They cover thirteen industry verticals, including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website http://www.marketsandmarkets.com
7557 Rambler Road,
Suite 727, Dallas, TX 75231